GAMMA SYNUCLEIN AGGREGATES AND GLAUCOMA
伽玛突触核蛋白聚集体和青光眼
基本信息
- 批准号:8361930
- 负责人:
- 金额:$ 2.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelBlindnessDataDiseaseElectron MicroscopyFundingFutureGamma synucleinGlaucomaGrantImage AnalysisImmunoelectron MicroscopyMusNational Center for Research ResourcesNatureNeurodegenerative DisordersOptic DiskParkinson DiseasePresynaptic TerminalsPrincipal InvestigatorRanaResearchResearch InfrastructureResourcesRetinal Ganglion CellsSourceTransgenic OrganismsUnited States National Institutes of Healthalpha synucleincellular pathologycostkillingsmouse modeloverexpression
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Glaucoma is a neurodegenerative disorder that kills retinal ganglion cells and is the second leading cause of blindness worldwide. Our recent data in multiple animal models of glaucoma suggest that this disease is characterized by pathological forms of gamma synuclein (Sncg) that resemble those seen for alpha synuclein in Parkinson's disease. In order to uncover the nature of these Sncg forms, we propose electron and immunoelectron microscopy analyses of the optic nerve head in a mouse model of glaucoma, the DBA/2J mouse, and of axons and terminals of transgenic frogs that overexpress tagged-Sncg in retinal ganglion cells. By demonstrating common cellular pathology in glaucoma and Parkinson's disease, the current studies stand to have a large impact on the current study and future treatment of these two equally common neurodegenerative disorders.
这个子项目是利用这些资源的众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NICHOLAS R MARSH-ARMSTRONG其他文献
NICHOLAS R MARSH-ARMSTRONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NICHOLAS R MARSH-ARMSTRONG', 18)}}的其他基金
Optic nerve head glymphatics and debris clearance in glaucoma
青光眼中的视神经乳头淋巴管和碎片清除
- 批准号:
10200062 - 财政年份:2018
- 资助金额:
$ 2.47万 - 项目类别:
Optic nerve head glymphatics and debris clearance in glaucoma
青光眼中的视神经乳头淋巴管和碎片清除
- 批准号:
10455455 - 财政年份:2018
- 资助金额:
$ 2.47万 - 项目类别:
Axonal mitochondria degradation as the Achilles heel of retinal ganglion cells
轴突线粒体降解是视网膜神经节细胞的致命弱点
- 批准号:
9899992 - 财政年份:2016
- 资助金额:
$ 2.47万 - 项目类别:
Axonal mitochondria degradation as the Achilles heel of retinal ganglion cells
轴突线粒体降解是视网膜神经节细胞的致命弱点
- 批准号:
9198767 - 财政年份:2016
- 资助金额:
$ 2.47万 - 项目类别:
Optic nerve head synucleinopathy in glaucoma and the function of gamma-synuclein
青光眼视神经乳头突触核蛋白病及γ-突触核蛋白的功能
- 批准号:
8500298 - 财政年份:2011
- 资助金额:
$ 2.47万 - 项目类别:
Optic nerve head synucleinopathy in glaucoma and the function of gamma-synuclein
青光眼视神经乳头突触核蛋白病及γ-突触核蛋白的功能
- 批准号:
8042280 - 财政年份:2011
- 资助金额:
$ 2.47万 - 项目类别:
Optic nerve head synucleinopathy in glaucoma and the function of gamma-synuclein
青光眼视神经乳头突触核蛋白病及γ-突触核蛋白的功能
- 批准号:
8298971 - 财政年份:2011
- 资助金额:
$ 2.47万 - 项目类别:
Role of a Novel Corepressor in Nuclear Receptor Action
新型辅阻遏物在核受体作用中的作用
- 批准号:
7217882 - 财政年份:2006
- 资助金额:
$ 2.47万 - 项目类别:
Role of a Novel Corepressor in Nuclear Receptor Action
新型辅阻遏物在核受体作用中的作用
- 批准号:
7369766 - 财政年份:2006
- 资助金额:
$ 2.47万 - 项目类别:
相似海外基金
Beyond the Visual: Blindness and Expanded Sculpture
超越视觉:失明与扩展的雕塑
- 批准号:
AH/Y005856/1 - 财政年份:2023
- 资助金额:
$ 2.47万 - 项目类别:
Research Grant
Innovative therapeutic strategies to support elimination of river blindness
支持消除河盲症的创新治疗策略
- 批准号:
10754120 - 财政年份:2023
- 资助金额:
$ 2.47万 - 项目类别:
Anatomical, neural, and computational constraints on sensory cross-modal plasticity following early blindness
早期失明后感觉跨模态可塑性的解剖学、神经学和计算限制
- 批准号:
10570400 - 财政年份:2023
- 资助金额:
$ 2.47万 - 项目类别:
Follow on to: Preventing avoidable blindness through smart home-monitoring of vision
继续:通过智能家居视力监测预防可避免的失明
- 批准号:
ES/Y001346/1 - 财政年份:2023
- 资助金额:
$ 2.47万 - 项目类别:
Research Grant
Establishment of preventive methods for blindness due to pathologic myopia by targeting CCDC102B
以CCDC102B为靶点建立病理性近视致盲预防方法
- 批准号:
23K09009 - 财政年份:2023
- 资助金额:
$ 2.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of neural compensation in the retina and dysfunction in congenital stationary night blindness
先天性静止性夜盲症视网膜神经代偿机制及功能障碍
- 批准号:
10678730 - 财政年份:2023
- 资助金额:
$ 2.47万 - 项目类别:
NSF Convergence Accelerator Track H: Phase II Smart Wearables for Expanding Workplace Access for People with Blindness and Low Vision
NSF 融合加速器轨道 H:第二阶段智能可穿戴设备,扩大失明和低视力人士的工作场所使用范围
- 批准号:
2345139 - 财政年份:2023
- 资助金额:
$ 2.47万 - 项目类别:
Cooperative Agreement
3D bioprinting of regenerative, corneal cell-laden inks to treat corneal blindness
3D 生物打印充满角膜细胞的再生墨水来治疗角膜失明
- 批准号:
10606474 - 财政年份:2023
- 资助金额:
$ 2.47万 - 项目类别:
From 'plant blindness' to 'bug blindness': disseminating an evidence-based pedagogy for plants and refining methodologies in attitudinal research
从“植物盲”到“虫盲”:传播植物循证教育学并完善态度研究方法
- 批准号:
ES/X007324/1 - 财政年份:2022
- 资助金额:
$ 2.47万 - 项目类别:
Fellowship